Evolution and Clinical Impact of PDE-5 Inhibitors

In the complicated and sometimes funny world of medical discoveries, phosphodiesterase type 5 (PDE5) inhibitors could be considered a lucky mistake. These molecules were first created in the late 1980s with the purpose of treating angina, a heart disease symptom which causes chest pain. At first, these substances did not bring a marked improvement to the cardiac symptoms.